KRATOS ENERGY & INFRASTRUCTURE LTD.

Lords Mark Industries Limited has announced the successful completion of Phase I of its expansion at the Silvassa facility, nearly three months ahead of its December 2026 target. This expansion increases their surgical and orthopaedic product portfolio from 36 to 54 SKUs. The new production line is set to commence commercial operations on October 11, 2026. The company's existing 36 products have US FDA approval, and the 18 new SKUs are expected to receive clearance before December 2026. This strategic move enhances manufacturing capabilities, expands market reach, and supports the company's global ambitions in the medical devices sector.

Lords Mark Industries Ltd announced that its Board of Directors, upon recommendation from the MPS Committee, has approved a proposal for an Offer for Sale (OFS). This OFS will involve the promoters selling up to 3% of the company's paid-up equity share capital. The move is aimed at achieving the Minimum Public Shareholding (MPS) requirement. The Board has authorized relevant directors and officers to undertake all necessary actions and filings for the proposed OFS.

Lords Mark Industries Ltd has announced its 46th Annual General Meeting (AGM) scheduled for Wednesday, September 30, 2026, at 11:30 AM IST. The meeting will be conducted via Video Conferencing/Other Audio Visual Means (VC/OAVM) in compliance with Ministry of Corporate Affairs and SEBI circulars. The Annual Report 2025-26 and the Notice of the AGM are being sent via email to members with registered email addresses and by letter with a web-link to others. Both documents are also available on the company's website (lordsmark.com) and BSE India's website. The company, with over 47 years of experience, operates in Healthcare & Diagnostics and LED/Solar solutions, with diversified investments in sister companies.

Lords Mark Industries Ltd has entered a strategic collaboration with ARKALL Holdings Ltd, a Caribbean-based entity, to establish and operate pathology laboratories and commercialize its medical devices and healthcare portfolio across the Caribbean region. ARKALL Holdings will provide the necessary investment for this expansion, which is planned in phases over three years, starting with Trinidad & Tobago. Lords Mark will supply its IVD products, medical equipment, and provide technical support. The company projects this phased rollout could generate approximately US$100 million in export revenue between FY 2026-27 and FY 2030-31. The estimated pathology and diagnostics market opportunity in the identified Caribbean markets is around US$1.24 billion.

Lords Mark Industries Ltd has published the extract of its unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2026. The results were approved by the Board of Directors on August 13, 2026, and published in 'Active Times' and 'Lakshdeep' on August 15, 2026. Key figures include Total Income from operations of ₹28,036.22 Lakhs (Standalone) and ₹44,198.11 Lakhs (Consolidated) for the quarter. Net Profit after tax stood at ₹3,216.44 Lakhs (Standalone) and ₹4,121.63 Lakhs (Consolidated). Earnings per share (basic and diluted) were ₹0.75 (Standalone) and ₹0.97 (Consolidated).

Lords Mark Industries Ltd has announced the calendar of events for its 46th Annual General Meeting (AGM). The AGM will be held on Wednesday, September 30, 2026, at 11:30 AM IST, conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The Board of Directors approved this schedule on August 13, 2026. Key dates include the cut-off date for voting on September 23, 2026, and the e-voting period which commences on September 27, 2026, and concludes on September 29, 2026. M/s. National Securities Depository Limited (NSDL) will provide e-voting services, and Ms. Geeta Serwani has been appointed as the scrutinizer.

Lords Mark Industries Ltd announced significant business developments across its diagnostics, medical devices, healthcare delivery, and renewable energy segments. The company projects consolidated revenue of at least ₹1,550 crore and PAT of ₹178 crore by FY2027, with substantial growth expected from FY2028 onwards driven by new ventures like sickle cell testing and medical devices. A key strategic move involves the proposed demerger of its renewable energy and LED division into a new entity, Lords Shakti Power Limited, by March 2027. Additionally, Lords Mark is entering into an exclusive agreement for CAR-T cell therapy in India, establishing a subsidiary in the UK and Switzerland for diagnostics, and launching oncology hospitals and a dialysis center network. These initiatives aim to broaden the healthcare platform and unlock value from its energy business.

Lords Mark Industries Ltd announced its unaudited standalone financial results for the quarter ended June 30, 2026. The company reported a total income of ₹28,522.32 Lakhs and a net profit of ₹3,216.44 Lakhs for the quarter. This compares to a net profit of ₹5,276.08 Lakhs for the quarter ended June 30, 2025. The Board of Directors approved these results along with the Limited Review Report from the statutory auditors.

Lords Mark Industries Ltd announced that its Board of Directors, in a meeting held on August 13, 2026, approved the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. The board also reviewed operational performance, strategic growth initiatives, and financial projections for FY 2026-27. Key decisions included noting the resignation of the Company Secretary & Compliance Officer, approving the notice for the 46th AGM scheduled for September 30, 2026, and appointing M/s Sanjeev S. Gupta & Associates as Statutory Auditors for a five-year term, subject to shareholder approval.

Lord's Mark Industries Limited has secured India's first manufacturing license for an In Vitro Diagnostic Software (Software as a Medical Device – SaMD) for its Biomescan Analytics Platform. This license, granted under the Medical Devices Rules, 2017, enables the company to bring gut microbiome science into mainstream preventive healthcare. The Biomescan platform analyzes whole metagenome sequencing data to provide personalized gut microbiome profiles and dietary recommendations. The company plans to establish a nationwide network of Health & Wellness Centres in collaboration with healthcare institutions to offer these personalized preventive care strategies.